image-title

MISSION STATEMENT/PHILOPSOPHY:

Oncology Consultants mission is a commitment to provide state-of-the-art cancer treatment in a caring environment.

LOCATION(S):

OC Pharmacy located in the Memorial City Area

OC Pharmacy II located in the Medical Center

OCRX Pharmacy Solutions located in the Katy Area

PRACTICE DETAILS (how many providers, how many employees, etc):

Oncology Consultants was formed 30+ years ago by Dr. Luis Campos to take care of patients in the Houston and outer Houston areas. We have 19 Oncologist/Hematologist, 3 Radiologists, 5 Nurse Practitioners, 6 Pharmacists, 10 Medical Offices with Infusion Suites, 2 Radiation Centers, 2 Imaging Centers, 3 Specialty Pharmacies.  We have over 250+ employees.

QUALIFICATIONS/CREDENTIALS (are you QOPI certified, etc.)

Oncology Consultants are:

  • One of the first practices in the nation to be QOPI certified.
  • CLIA certified by CMS – Clinical Laboratory Improvements Amendment.
  • Our nurses are ONS certified through the Oncology Nursing Certification Corporation.
  • Our Physicians are recognized every year in the Houstonian Magazine as Top Doctors, and recognized in Texas Monthly Magazines as Super Doctors of Texas by their peers.
  • ACR accredited – American College of Radiology accreditation for PET, CT, and Ultrasound.
  • Our pharmacies have recently submitted for dual accreditation with URAC and ACHC.

INTRODUCTION TO PHARMACY SERVICES STAFF W/ BRIEF BIO:

(insert staff photo if you have one)

OC Pharmacy was establish 17 years ago.  Yen Nguyen started managing the pharmacy 14+ years ago.  Since then, we have grown to 3 retail pharmacies and we have been the number one producing pharmacy in Oncology Circle for the last 6 years.

OC Pharmacy Staff consist of:

Director of Pharmacy

3 FTE Pharmacist-in- Charge

1 FTE Adherence Pharmacist

1 Oncolytic Nurse Navigator

1 PT Pharmacist for coverage

7 FTE Pharmacy Technicians (2-3 per pharmacy)

1 FTE Compliance Senior Technician

1 FTE Prior Authorization Central Technician

1 FTE AR Technician

1 PT Clerk

WHY DID  YOU JOIN NCODA?

I joined NCODA about 4 years ago because I wanted to join an organization that was diversified and open to all levels of practices large or small. I appreciate that NCODA’s focus is always on the patient, the sharing of best practices, and the comraderies between all levels of practices.

HOW DID YOU BECOME A MEMBER?

I had the pleasure of meeting Mike Reff 4 years ago at an ad board when NCODA was about 2 years old. We discussed a few ideas, and I was able to help him rebrand the NCODA logo and website. We created the NCODA Cost Avoidance & Wastage Tracker too and the Financial Assistance resource.

HOW CAN NCODA HELP YOU?

I love the sharing of best practice ideas, Oral Chemo Education Sheets, Clinical Corners, PQIs. There is so much pharmacy talent throughout the country. I utilize these resources continuously to improve my practice.

WHAT ARE SOME CHALLENGES YOU FACE NOW OR WILL FACE IN THE FUTURE OF ONCOLOGY?

Year on year decrease in Medicare payment resulting in more negative margin claims, managing the challenges of DIR fees, and the financial toxicity of oral oncolytics.

Read More

NCODA Spring Forum 2020 Transitions to Virtual E-Meeting

March 10, 2020 3pm Eastern

To our valued members and corporate partners,

In alignment with our Guiding Values, 1) Patient-Centered and 2) Always Collaborative, NCODA is taking all necessary precautions in order to provide our members and corporate partners a value-added experience, while remaining vigilant concerning the health and safety concerns surrounding the coronavirus outbreak.

Our top priority is the health and safety of our patients, members, exhibitors, and meeting faculty. We have a moral and professional obligation to do what we can individually and collectively to minimize the spread of this outbreak. It’s about keeping oncology patients safe. They are immunocompromised and many have comorbidities; our responsibility is to abide by the policies and procedures created to ensure the safety of patients.

Therefore, we have made the decision to cancel the 2020 NCODA Spring Forum in Dallas, Texas (March 18-20). We understand that our meetings provide members and partners with updates and sharing of best practices, and we realize participants get firsthand information that they can use to enhance care at their respective practices.

When important meetings, like the NCODA Spring Forum, get canceled it’s a major disruption in dissemination of vital information. Keeping this in mind, NCODA will be converting the Spring Forum into an e-meeting format that will take place on Thursday, March 19th from 8am – 6pm eastern. All registered participants will be contacted via email with the necessary e-meeting sign-in details.

NCODA is committed to fulfilling our Mission of disseminating critical oncology information. We intend to provide a rich alternative meeting and learning experience for the oncology community. We will provide more information about cancellation logistics, including registration, hotel, and flight accommodations, in the near future. Please stay tuned for more information. See the full press release here.

Please email Kristen Ray (kristen.ray@ncoda.org) with any questions.

Read More

BRIDGEWATER, N.J.March 2, 2020 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Sarclisa is expected to be available to patients in the U.S. shortly.

Sarclisa is a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells.

“Today’s FDA approval of Sarclisa provides a new treatment option for patients with difficult-to-treat multiple myeloma. These are patients whose disease has returned or become resistant to their prior treatments,” said Paul Hudson, Chief Executive Officer, Sanofi. “At Sanofi, we are focused on discovering and developing medicines that may change the practice of medicine, and Sarclisa offers a potential new standard of care in the United States. We continue to evaluate Sarclisa in a comprehensive clinical program in multiple myeloma, as well as in other blood cancers and solid tumors.” Learn More Here

Read More